Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
Shuman Glenn & Stecker Investigates Corcept Therapeutics, Inc.
12:00am, Wednesday, 05'th Aug 2020
Shuman, Glenn & Stecker Investigates Corcept Therapeutics, Inc.
Corcept Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
08:05pm, Tuesday, 04'th Aug 2020
MENLO PARK, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
ABIOMED, Inc. (NASDAQ: ABMD)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Annexon Inc (NASDAQ: ANNX)
Atossa...
Composite Rating For Emergent Biosolutions Rises To 99
10:27pm, Monday, 03'rd Aug 2020
Emergent Biosolutions saw its IBD SmartSelect Composite Rating jump to 99 Monday, up from 94 the day before. The upgrade means the stock currently tops 99% of all other stocks in terms of key performa
Did Hedge Funds Make The Right Call On Corcept Therapeutics Incorporated (CORT) ?
05:00pm, Monday, 03'rd Aug 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
What Kind Of Investors Own Most Of Corcept Therapeutics Incorporated (NASDAQ:CORT)?
03:26pm, Monday, 03'rd Aug 2020
A look at the shareholders of Corcept Therapeutics Incorporated (NASDAQ:CORT) can tell us which group is most...
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
08:05pm, Tuesday, 28'th Jul 2020
MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on
Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing’s Syndrome of Adrenal Origin
12:30pm, Tuesday, 28'th Jul 2020
MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met
Moderna's Patent Snub, And Other News: The Good, Bad And Ugly Of Biopharma
09:36am, Monday, 27'th Jul 2020
Moderna has mixed luck with patent snub, but moves ahead with COVID-19 vaccine. Sorrento advances acquisition of SmartPharm.
MENLO PARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Acquired by SG Americas Securities LLC
08:54am, Wednesday, 22'nd Jul 2020
SG Americas Securities LLC lifted its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 39.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Ex
Valeo Financial Advisors LLC Has $213,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)
07:32am, Wednesday, 22'nd Jul 2020
Valeo Financial Advisors LLC lowered its position in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 28.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchan
New GuruFocus Feature: Warren Buffett's Baskets
11:08pm, Tuesday, 21'st Jul 2020
GuruFocus users can now assign stocks into one of several baskets Continue reading...
Corcept Therapeutics: A Long-Term Hold Despite Short-Term Sales Threat
02:08pm, Monday, 13'th Jul 2020
Corcept is a rare biotech that pays for its own operations thanks to the triple-digit-million sales of its cortisol modulating treatment for Cushing's Syndrome, Korlym.
